viewAdmedus Ltd

Admedus in trading halt with sale transaction news pending

The trading halt will remain in place until an announcement is made or until the beginning of trade on April 12, 2019.

Shares last traded at 9.2 cents per share

Admedus Ltd (ASX:AHZ) is in a trading halt pending an announcement regarding an Admedus Immunotherapies sale transaction and a response to price query from the ASX.

The company’s securities will remain in trading halt until Friday April 12, 2019 or when the announcement is made to market.

READ: Admedus delivers results with heart-driven corporate strategy

Early last month Admedus received regulatory approval in the form of the CE Mark for its CardioCel 3D product portfolio and its collagen bioscaffold VascuCel in Europe.

The company intends to begin the first phase of its commercial launch of CardioCel 3D after having worked with selected key opinion leaders familiar with the technology.

Quick facts: Admedus Ltd

Price: 4.35 AUD

Market: ASX
Market Cap: $25.71 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Admedus Ltd named herein, including the promotion by the Company of Admedus Ltd in any Content on the Site, the Company receives from said...



Admedus CEO in New York to update on recent key milestones

Admedus Ltd (ASX:AHZ) CEO Wayne Paterson visited the Proactive Investors New York studio to update on key milestones the company has achieved in the past few months, including receiving European approval on two of its products.

on 03/17/2019

2 min read